Tai-Kuang Chao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1542370/publications.pdf

Version: 2024-02-01

567281 477307 33 884 15 29 citations h-index g-index papers 33 33 33 1753 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Histopathological whole slide image dataset for classification of treatment effectiveness to ovarian cancer. Scientific Data, 2022, 9, 25.	5.3	7
2	Ovarian steroid cell tumor causing isosexual pseudoprecocious puberty in a young girl: an instructive case and literature review. BMC Endocrine Disorders, 2022, 22, 41.	2.2	1
3	A Weakly Supervised Deep Learning Method for Guiding Ovarian Cancer Treatment and Identifying an Effective Biomarker. Cancers, 2022, 14, 1651.	3.7	18
4	The MTNR1A mRNA is stabilized by the cytoplasmic hnRNPL in renal tubular cells. Journal of Cellular Physiology, 2021, 236, 2023-2035.	4.1	4
5	Deep Learning Fast Screening Approach on Cytological Whole Slides for Thyroid Cancer Diagnosis. Cancers, 2021, 13, 3891.	3.7	29
6	Artificial intelligence-assisted fast screening cervical high grade squamous intraepithelial lesion and squamous cell carcinoma diagnosis and treatment planning. Scientific Reports, 2021, 11, 16244.	3.3	33
7	AlM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients. Journal of Clinical Medicine, 2021, 10, 4529.	2.4	10
8	Loss of ten-eleven translocation 1 (TET1) expression as a diagnostic and prognostic biomarker of endometrial carcinoma. PLoS ONE, 2021, 16, e0259330.	2.5	6
9	TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target. Journal of Pathology, 2019, 248, 363-376.	4.5	23
10	TET1 promotes 5hmC-dependent stemness, and inhibits a 5hmC-independent epithelial-mesenchymal transition, in cervical precancerous lesions. Cancer Letters, 2019, 450, 53-62.	7.2	33
11	Pyruvate Kinase M2 Expression: A Potential Metabolic Biomarker to Differentiate Endometrial Precancer and Cancer That Is Associated with Poor Outcomes in Endometrial Carcinoma. International Journal of Environmental Research and Public Health, 2019, 16, 4589.	2.6	10
12	Role of melatonin receptor 1A and pituitary homeoboxâ€1 coexpression in protecting tubular epithelial cells in membranous nephropathy. Journal of Pineal Research, 2018, 65, e12482.	7.4	14
13	The combination of aldehyde dehydrogenase 1 (ALDH1) and CD44 is associated with poor outcomes in endometrial cancer. PLoS ONE, 2018, 13, e0206685.	2.5	15
14	<i>O</i> â€Glycosylationâ€mediated signaling circuit drives metastatic castrationâ€resistant prostate cancer. FASEB Journal, 2018, 32, 6869-6882.	0.5	49
15	Epigenetic loss of heparan sulfate 3â€ <scp>O</scp> â€sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis. International Journal of Cancer, 2018, 143, 1943-1953.	5.1	11
16	Adult-onset Langerhans cell histiocytosis of the sternum. Journal of Thoracic Disease, 2017, 9, E783-E786.	1.4	4
17	Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. PLoS ONE, 2017, 12, e0182166.	2.5	39
18	Gestational choriocarcinoma with renal and pulmonary metastases lacking a primary uterine origin. Taiwanese Journal of Obstetrics and Gynecology, 2016, 55, 881-885.	1.3	10

#	Article	IF	CITATIONS
19	Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4- <i>O</i> -Glycan to Cancer Cells. Cancer Research, 2016, 76, 5756-5767.	0.9	54
20	Paired boxed gene 1 expression: A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma. Journal of Obstetrics and Gynaecology Research, 2016, 42, 1159-1167.	1.3	3
21	Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer. Oncotarget, 2016, 7, 8993-9006.	1.8	66
22	Life-threatening hematuria in a hemodialysis patient with systemic light-chain amyloidosis. Clinica Chimica Acta, 2015, 451, 180-182.	1,1	1
23	Hypermethylation of the TGF- \hat{l}^2 target, ABCA1 is associated with poor prognosis in ovarian cancer patients. Clinical Epigenetics, 2015, 7, 1.	4.1	133
24	Interpositional Arthroplasty With Palmaris Longus Tendon Graft for Osteonecrosis of the Second Metatarsal Head: A Case Report. Journal of Foot and Ankle Surgery, 2015, 54, 237-241.	1.0	14
25	Annexin A2 in renal cell carcinoma: Expression, function, and prognostic significance. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 22.e11-22.e21.	1.6	33
26	Urine Annexin A1 as an Index for Glomerular Injury in Patients. Disease Markers, 2014, 2014, 1-12.	1.3	16
27	DNA methylation as a biomarker for the detection of hidden carcinoma in endometrial atypical hyperplasia. Gynecologic Oncology, 2014, 135, 552-559.	1.4	28
28	R1933X mutation in the MYH9 gene in May-Hegglin anomaly mimicking idiopathic thrombocytopenic purpura. Journal of the Formosan Medical Association, 2014, 113, 56-59.	1.7	7
29	Malignant Potential of Endometrial Stromal Tumor With Limited Infiltration. International Journal of Surgical Pathology, 2014, 22, 559-563.	0.8	10
30	Rare case of a paratubal cystadenoma with bilateral hydrosalpinges in an infertile woman. Taiwanese Journal of Obstetrics and Gynecology, 2014, 53, 239-240.	1.3	2
31	Triage of cervical cytological diagnoses of atypical squamous cells by DNA methylation of <i>paired boxed gene 1 (PAX1)</i> . Diagnostic Cytopathology, 2013, 41, 41-46.	1.0	29
32	LIM-homeobox transcription factor 1, alpha (LMX1A) inhibits tumourigenesis, epithelial–mesenchymal transition and stem-like properties of epithelial ovarian cancer. Gynecologic Oncology, 2013, 128, 475-482.	1.4	22
33	ALDH1-Bright Epithelial Ovarian Cancer Cells Are Associated with CD44 Expression, Drug Resistance, and Poor Clinical Outcome. American Journal of Pathology, 2012, 180, 1159-1169.	3.8	150